Caloric reset driven by GLP-1 drugs could cut food volumes by over 10%

While only 2–3% of U.S. adults currently use GLP-1s, the bank expects adoption could reach high single digits in five years, with long-term potential near 35%, comparable to statin use, given rising prescriptions, future oral versions, and broader insurance coverage. Volume losses would likely be gradual, about 1–2% annually, but could accelerate as drug use scales, the note said. Categories with the highest exposure include Hershey, Mondelez (NASDAQ:MDLZ), Smucker, and Hostess-parent Flowers Foods (NYSE:FLO), due to their sugar and fat content. Keurig Dr Pepper (NASDAQ:KDP) was cited for its exposure in beverages.
In contrast, companies with higher fiber or protein content in their portfolios, such as Conagra and General Mills (NYSE:GIS), are better positioned, while others may be forced to reformulate products or pivot through acquisitions. The note flagged that adapting to changing dietary trends could be costly, especially as GLP-1 users seek more nutrient-dense, satiating foods. Manufacturers may face growing pressure to reshape portfolios faster than current bolt-on M&A strategies suggest, according to the analysts.